References

Barsanti JA., Finco DR., Shotts EB., Ross L. Feline urologic syndrome: further investigation into therapy. Journal of the American Animal Hospital Association. 1982; 18:387-90

Beata C, Beaumont-Graff E, Coll V Effect of alpha-casozepine (Zylkene) on anxiety in cats. Journal of Veterinary Behaviour. 2007; 2:(2)40-6

Buffington CAT. Idiopathic Cystitis in Domestic Cats-Beyond the Lower Urinary Tract. J Vet Intern Med. 2011; 25:(4)784-96 https://doi.org/10.1111/j.1939-1676.2011.0732.x

Buffington CA, Pacak K. Increased plasma norepinephrine concentration in cats with interstitial cystitis. J Urol.. 2001; 165:(6 Pt 1)2051-4

Buffington CAT, Chew DJ, Woodworth BE. Animal model of human disease—feline interstitial cystitis. Comp Path Bull. 1997; 29:3-6

Buffington CA, Westropp JL, Chew DJ, Bolus RR. Clinical evaluation of multimodal environmental modification (MEMO) in the management of cats with idiopathic cystitis. J Feline Med Surg. 2006; 8:(4)261-8

Cameron ME, Casey RA, Bradshaw JW, Waran NK, Gunn-Moore DA. A study of environmental and behavioural factors that may be associated with feline idiopathic cystitis. J Small Anim Pract.. 2004; 45:(3)144-7

Caston H. Stress and the feline urological syndrome. Feline Practice. 1973; 3:14-22

Chew DJ, Buffington CA, Kendall MS, DiBartola SP, Woodworth BE. Amitriptyline treatment for severe recurrent idiopathic cystitis in cats. J Am Vet Med Assoc.. 1998; 213:(9)1282-6

Cozzi A, Monneret P, Lafont-Lecuelle C, Bougrat L, Gaultier E, Pageat P. The maternal cat appeasing pheromone: Exploratory study of the effects on aggressive and affiliative interactions in cats. Journal of Veterinary Behaviour: Clinical Applications and Research. 2010; 5:(1)27-38

De-Stress-new natural product for relief from stress and anxiety. 2013. http://www.drdebe.com/articles/de-stress-new-natural-product-for-relief-from-stress-anxiety (accessed 7th May, 2020)

Defauw PA, Van de Maele I, Duchateau L, Polis IE, Saunders JH, Daminet S. Risk factors and clinical presentation of cats with feline idiopathic cystitis. J Feline Med Surg.. 2011; 13:(12)967-75 https://doi.org/10.1016/j.jfms.2011.08.001

Dorsch R., Zellner F., Schulz B., Louis C., Hartmann K. J Feline Med Surg.. 2016; 18:(11)925-33 https://doi.org/10.1177/1098612X15621603

The science behind Feliway. 2017. https://www.feliway.com/us/Products/FELIWAY-messages (accessed 12th May, 2020)

Forrester SD, Roudebush P. Evidence-based management of feline lower urinary tract disease. Vet Clin North Am Small Anim Pract. 2007; 37:(3)533-58

Forrester SD, Towell TL. Feline Idiopathic Cystitis. Vet Clin North Am Small Anim Pract. 2015; 45:(4)783-806 https://doi.org/10.1016/j.cvsm.2015.02.007

Gerber B, Boretti FS, Kley S Evaluation of clinical signs and causes of lower urinary tract disease in European cats. J Small Anim Pract. 2005; 46:(12)571-7

Gunn-Moore D.A., Shenoy C.M. Oral Glucosamine and the management of FIC. Journal of Feline Medicine and Surgery. 2004; 6:(4)219-225

Gunn-Moore DA, Cameron ME. A pilot study using synthetic feline facial pheromone for the management of feline idiopathic cystitis. J Feline Med Surg. 2004; 6:(3)133-8

Gunn-Moore D.A. Managing Feline cystitis long term. Veterinary Times. 2014; 44:(25)20-21

Ikeda Y, Birder L, Buffington C, Roppolo J, Kanai A. Mucosal muscarinic receptors enhance bladder activity in cats with feline interstitial cystitis. J Urol.. 2009; 181:(3)1415-22 https://doi.org/10.1016/j.juro.2008.10.138

Kirk H. Retention of urine and urine deposits. In: Kirk H (ed). London: Bailliere, Tindall and Cox; 1925

Kruger JM, Conway TS, Kaneene JB Randomized controlled trial of the efficacy of short-term amitriptyline administration for treatment of acute, nonobstructive, idiopathic lower urinary tract disease in cats. J Am Vet Med Assoc.. 2003; 222:(6)749-58

Lekcharoensuk C, Osborne CA, Lulich JP. Epidemiologic study of risk factors for lower urinary tract diseases in cats. J Am Vet Med Assoc.. 2001; 218:(9)1429-35

Lund HS, Skogtun G, Sørum H, Eggertsdóttir AV. Absence of bacterial DNA in culture-negative urine from cats with and without lower urinary tract disease. J Feline Med Surg.. 2015; 17:(10)909-14 https://doi.org/10.1177/1098612X14563098

Markwell PJ, Buffington CA, Chew DJ, Kendall MS, Harte JG, DiBartola SP. Clinical evaluation of commercially available urinary acidification diets in the management of idiopathic cystitis in cats. J Am Vet Med Assoc.. 1999; 214:(3)361-5

Meyer H.P. Effects of a urinary food supplemented with milk protein hydrolysate and L-tryptophan on feline idiopathic cystitis-results of a case series in 10 cats. International Journal of applied research in veterinary medicine. 2016; 14:(1)59-65

Osborne CA, Kruger JM, Lulich JP Prednisolone therapy of idiopathic feline lower urinary tract disease: a double-blind clinical study. Vet Clin North Am Small Anim Pract.. 1996; 26:(3)563-9

Reche Júnior A, Buffington CA. Increased tyrosine hydroxylase immunoreactivity in the locus coeruleus of cats with interstitial cystitis. J Urol.. 1998; 159:(3)1045-8

Reineke EL, Thomas EK, Syring RS, Savini J, Drobatz KJ. The effect of prazosin on outcome in feline urethral obstruction. J Vet Emerg Crit Care (San Antonio). 2017; 27:(4)387-96 https://doi.org/10.1111/vec.12611

Sævik BK, Trangerud C, Ottesen N, Sørum H, Eggertsdóttir AV. Causes of lower urinary tract disease in Norwegian cats. J Feline Med Surg.. 2011; 13:(6)410-7 https://doi.org/10.1016/j.jfms.2010.12.012

Sparkes A. Understanding feline idiopathic cystitis. Vet Rec.. 2018; 182:(17) https://doi.org/10.1136/vr.k1848

Stella JL, Lord LK, Buffington CA. Sickness behaviours in response to unusual external events in healthy cats and cats with feline interstitial cystitis. J Am Vet Med Assoc.. 2011; 238:(1)67-73 https://doi.org/10.2460/javma.238.1.67

Taylor S. Management of urinary tract disorders. BSAVA Manual of Feline Practice: A Foundation Manual. 2013;

British Small Animal Veterinary Association, Gloucester: Chapter 13 VetCompass. Demographic Information on UK cats. 2019. https://www.rvc.ac.uk/vetcompass/learn-zone/infographics/uk (Accessed on 27th December 2019)

Veranic P, Jezernik K. The response of junctional complexes to induced desquamation in mouse bladder urothelium. Biol Cell. 2000; 92:(2)105-13

Westropp JL, Welk KA, Buffington CA. Small adrenal glands in cats with feline interstitial cystitis. J Urol.. 2003; 170:(6 Pt 1)2494-7

Westropp JL, Kass PH, Buffington CA. Evaluation of the effects of stress in cats with idiopathic cystitis. Am J Vet Res.. 2006; 67:(4)731-6

Feline idiopathic cystitis: what to suggest

02 May 2020
9 mins read
Volume 11 · Issue 4
Figure 1. Feline idiopathic cystitis has a range of clinical signs, a common one being inappropriate urination.

Abstract

This paper reviews the available evidence for the treatments for feline idiopathic cystitis (FIC). The true pathophysiology of FIC can vary between patients, and includes intrinsic abnormalities, increased sensitivity to stressors, reduced nerve sensitivity or an abnormal sympathoneural outflow. Current treatment for FIC involves a variety of medications including analgesia, antibiotics, nutraceuticals, antispasmodics, environmental modification and diet alteration. Environmental changes have been shown to reduce the occurrence of symptoms; however, the trials indicating this were uncontrolled because of the number of changing variables. Evidence for the use of medications is lacking, identifying the need for further research in this area.

Feline idiopathic cystitis (FIC) is the most common pathology under the umbrella term of feline lower urinary tract disease (FLUTD), affecting 55–65% of all patients with FLUTD (Sparkes, 2018).

FIC has a range of clinical signs including dysuria, stranguria, pollakiuria, periuria, haematuria, urethral blockage and pain (Buffington, 2011), with these being shown most commonly by spraying, overgrooming, vocalising, straining, anorexia, nervousness and aggression (Figure 1) (Sparkes, 2018). Identifying the most appropriate treatment for FIC can help prevent reoccurrence, improving the patient's quality of life and reducing risk of rehoming or euthanasia.

Figure 1. Feline idiopathic cystitis has a range of clinical signs, a common one being inappropriate urination.

Pathogenesis

Because of the wide range of symptoms and presentations it is likely that FIC has multiple causes (Forrester and Towell, 2015).

Stress has been suggested as being integrally involved in FIC (Ikeda et al, 2009). In these patients, the sympathoneural outflow increases without activating the adrenal cortex, and the adrenocorticotropic hormone (ACTH) stimulation is reduced, reducing the cat's ability to cope with stress (Buffington, 2011). Studies completed on this hypothesis are mixed, with one exposing cats to stressful stimuli with no affect (Stella et al, 2011) and others identifying the following distinct neurohormonal abnormalities:

  • Increased plasma norepinephrine without a concurrent increase in cortisol or adrenocorticotropic hormone (Westropp et al, 2006)
  • Increased tyrosine hydroxylase immunoreactivity in the locus coeruleus, causing increased sympathetic activity (Reche and Buffington, 1998)
  • Reduced response to the existing adrenocorticotropic hormone and a reduced volume of adrenal gland, compared with cats without FIC (Westropp et al, 2003).

Bladder abnormalities are also apparent in cats with FIC, that indicate neurohormonal changes are not a single risk factor:

  • The glycosaminoglycan (GAG) layer may be abnormal, either decreased or there may be variations in the quality (Buffington, 2011), allowing urinary solutes to cause tissue injury (Forrester and Towell, 2015). Factors such as an altered pH, electrolyte imbalance and infection can weaken the function of the GAG layer and cause damage (Buffington, 2011).
  • Dorsal root ganglion cell bodies were found to be 30% larger, and to be desensitising (Buffington, 2011), potentially causing the patient to not express their bladder as frequently as normal. Impaired mobility, confinement, litter tray availability and cleanliness, inter-cat aggression and anxiety (Forrester and Towell, 2015) can also cause a decrease in urination.
  • Abnormalities in the urothelium, detrusor and submucosa after a period of stress have been identified in a study on mice (Veranic and Jezernik, 2000), however it is not known if this study is comparable to feline anatomy, and if the damage found in the urothelium is a cause or effect of FIC.
  • Mast cells have been identified in the submucosa in biopsy specimens of 20% of cats with idiopathic cystitis, potentially as a by-product of the stress concurrent with FIC, or related to the cause (Buffington et al, 1997). The relatively small percentage indicates that if this is the cause, it is not the only one.

Although these studies have not been able to confirm any particular causative factor, they have identified that bladder abnormalities and neurohormonal changes have occurred in cats with FIC and may be part of the pathogenesis.

Epidemiology

FIC is seen across all breeds and ages ranges, with 5–6-year-old cats being commonly affected (Dorsch et al, 2016). Research in Europe (Saevik et al, 2011) and America (Lekcharoensuk et al, 2001) has found a higher number of males being affected, however the risk of urethral obstruction (Gerber et al, 2005) could increase numbers seeking veterinary attention compared with female cat's, leading to unintentional bias. Risk factors are varied, with a Scottish study identifying overweight males in conflict-filled house-olds to be more at risk (Cameron et al, 2004), and a Belgian and Norwegian study identifying that the household environment was not a factor, and body condition score and disposition were more important (Defauw et al, 2011).

Treatment options

Nutraceuticals

GAG supplements available are N-acetyl, D-glucosamine (precursors of glycosaminoglycan) and hyaluronic acid (main component of the GAG layer). Overall studies to test the benefits of GAG supplements in 40 cats suffering from FIC for 6 months have returned results with no significant difference between the placebo and the supplement (Gunn-Moore and Shenoy, 2004).

Alpha-casozepine is a product derived from a protein in the milk molecule casein. Alpha-casozepine acts directly on the brain through the same neuro transmitter (gamma aminobutyric acid) that benzodiazepines act on, producing a calming effect (Debe, 2013). This product is designed to reduce stress and anxiety in patients and has been used to reduce the stress element of FIC and reduce the likelihood of developing FIC (Buffington and Pacak, 2001). Studies on anxious cats have shown that after a 56-day trial all participants showed signs of improvement for a range of social phobias including aggression, fears and autonomic disorders (Beata et al, 2007).

L-tryptophan is a precursor to serotonin synthesis, which regulates anxiety and mood. An increase in serotonin can act as an anxiolytic (Forrester and Towell, 2015). This supplement is combined with either a GAG supplement or milk proteins such as alpha casozepine, so it is difficult to assess the effectiveness of its use alone. A 2-month study identified that supplementation with L-tryptophan significantly changed the frequency of stress-related behaviours, decreasing signs of anxiety, however this was not applied directly to FIC (Pereira et al, 2010).

Pheromones

The F3 feline facial pheromone (FFP) is spread via the cat's cheeks, pads and body, providing comfort and reassurance (Feliway, 2017).

A study completed by Gunn-Moore and Cameron (2004) tested the wellbeing and FIC signs of nine cats that were exposed to FFP or a placebo in the environment for 2 months. Visual signs were recorded by the owners and compared against a scale to assess clinical and behavioural changes. At the end of the study five of the owners had reported overall improvements. However, on examination of the results it was shown that when the cats were exposed to FFP the periods of cystitis were reduced and the days spent with clinical signs were also reduced (Gunn-Moore and Cameron, 2004). This shows a positive outcome for the use of FFP in the treatment of FIC.

The cat appeasing pheromone (CAP) is derived from the pheromone that queens produce from their mammary glands. This has a soothing effect on the kittens and can keep cohesion between them (Cozzi et al, 2010). If FIC is triggered by stress from other cats within the environment, then using cat appeasing pheromones to alleviate tension, will help to alleviate symptoms of FIC. A study to test the effects of CAP was completed in 2010 by Cozzi et al (2010) which compared the reactions of 16 cats, in pairs, when confronted with a potentially conflicting situation. Those exposed to CAP showed a slight increase in the duration of harmonious exchanges and spent a longer time in proximity to other cats in comparison to the placebo group (Cozzi et al, 2010). Although this study was not related to cats with FIC, an improvement in agreeable cat–cat relations can reduce stress and reduce the severity and length of symptoms.

Nutrition

Nutrition, specifically feeding a wet food diet with more than 60% moisture, is the only treatment that is associated with a significant reduction of clinical signs (Forrester and Roudebush, 2007). Increasing the patient's water intake results in urine that is more dilute and causes less neurogenic bladder inflammation (Figure 2) (Taylor, 2013). The easiest way of increasing water intake is to introduce a wet diet. In a year-long study involving 46 cats being fed a dry urinary diet (n=28) or a wet version of the same diet (n=18), the clinical signs of FIC occurred less frequently in those fed the wet diet, with 16/18 (88%) not developing any signs, compared with 17/28 (60%) (p<0.05) (Markwell et al, 1999).

Figure 2. Increasing the patient's water intake results in urine that is more dilute, causing less bladder inflammation.

Environmental enrichment

Anxiety related to the environment can add further strain onto any stress-related abnormalities in the neuroendocrine system, causing a decreased frequency of urination (Forrester and Towell, 2015). The environment is a large part of the cat's life, and is often uncontrollable, especially if the cat goes outside.

The hypothesis that environmental stressors can exacerbate either symptoms or occurrence of FIC originally came from Kirk (1925) who suggested that confinement to the house would contribute to FIC. Following an earthquake in California, Caston (1973) identified an increase in cats suffering from FIC and suggested a treatment of ‘determine the stress and where possible, remove it’.

Environmental modification enhances the environment in line with the cat's behavioural biology. Providing the cat with options and allowing choice encourages appropriate behaviours and can help prevent inter-cat aggression. This includes providing enough necessary resources which contain outlets for the feline's normal behaviours (scratching, hunting, playing, resting, eliminating, chewing and hiding (Forrester and Towell, 2015) for all cats in the household. A general rule is to provide one of every resource per cat, plus one additional (Harvey and Tasker, 2013).

Creating predictable routines between the owner and the cat can also help reduce any stress. This allows the cat to foresee any potential stressors and avoid them, therefore decreasing the central noradrenergic drive (Forrester and Towell, 2015).

Environmental modification is a difficult treatment to analyse and evaluate. A study in a controlled laboratory setting measured catecholamine concentrations and urinary bladder permeability after FIC cats were exposed to stressful and enriched environments. It showed that those exposed to the enriched environment had reduced catecholamine concentrations and bladder permeability, thus having a beneficial effect for FIC (Forrester and Towell, 2015). A prospective study was completed by Buffington et al (2006) which evaluated 46 FIC cats under environmental modification, either alone, or in addition to drug therapy. For 10 months no signs of FIC were identified in 70–75% of the cats, and of those that did show signs, they resolved without further intervention. General fearfulness, nervousness, respiratory signs and gastro-intestinal signs were also reduced. This study showed that the addition of environmental modification reduced the output of the stress response system, thus improving FIC. Despite the prospective study showing positive results, Buffington (2006) identified that individual responses to changes in the environment depend on the cat's history, and what works for one, may not work for others, making it difficult to prove efficacy (Figure 3).

Figure 3. Modifying internal environments will depend on the individual circumstance and preferences.

Drug therapy

In randomised clinical trials of the efficacy of treatment for the management of FIC, no drug therapy has been shown to be effective (Sparkes, 2018), and the additional stress of giving medication may contribute to reoccurrence of clinical signs (Buffington, 2011). Recommended drug therapy can differ depending on the patient's clinical signs; however, the administration of analgesia is recommended at all times to alleviate pain and discomfort (Sparkes, 2018).

Non-steroidal anti-inflammatory drugs (NSAIDS) have been shown to improve pain in cats post urethral obstruction, however in a study on 37 cats receiving either meloxicam (n=18) orally or a placebo (n=19) for 5 days post obstruction it was identified that meloxicam did not have a significant benefit. Four (22%) of the meloxicam patients developed repeat obstruction over a period of 3 months compared with five (26%) of the placebo patients (Dorsch et al, 2016). However, this study was using meloxicam as a short-term measure, and the use of meloxicam to relieve symptoms of FIC as they occur may be of benefit to help prevent urethral obstruction.

In the treatment of FIC, a study of 12 cats looking at the efficacy of prednisolone showed that it was no more effective than the offered placebo at reducing the severity or duration of clinical signs (Osborne et al, 1996). This study was only completed over a period of 4 weeks, and the cats were hospitalised during this time for observation, which could have counteracted any benefit of the medication due to the stress of being hospitalised. Dysuria resolved in the cats receiving both the prednisolone and the placebo after 1.5 days, however this was put down to the self-limiting nature of FIC.

Amitriptyline is a tricycle antidepressant with analgesic and anti-inflammatory properties. An uncontrolled study of 15 cats, showed that administration of amitriptyline for 12 months decreased FIC signs for 9/15 (60%) of patients in the last 6 months (Chew et al, 1998). Haematuria and proteinuria were decreased in all cats at the 12-month mark, however abnormalities were evident on cystoscopy at 6 and 12 months post treatment (Chew et al, 1998). When used short term for 7 days in a study involving 31 cats, there was no difference in the rate of recovery from pollakiuria or haematuria, however those treated with the amitriptyline had faster rates of reoccurrence and suffered more frequently than those treated with the placebo (Kruger et al, 2003). These studies indicate that longer use of amitriptyline may help reduce reoccurrence of FIC, potentially by reducing the stress response.

Antimicrobials are a common treatment despite being rarely indicated. This may be due to suspected infection or as antimicrobials are often associated with a resolution due to the self-limiting nature of FIC. However, a study with chloramphenicol showed no real difference in resolution of clinical signs when compared with placebo (Barsanti et al, 1982). A study in Norway showed that 33% of cats with urinary tract signs had bacteriuria (Lund et al, 2015) so it is possible that the cats in the afore mentioned study did not have a positive culture or required differing antibiotics. Due to risk of antimicrobial resistance within companion animals, treatment should be based on urine culture and sensitivity results.

A small study of 47 cats with urinary obstruction, compared prazosin vs a placebo when administered for 1 month following obstruction. Cats were monitored for 6 months for repeat urethral obstruction. It was identified that there was no difference between the rate of reoccurrence or the severity of signs throughout the time frame (Reineke et al, 2017). Prazosin was only administered for 1 month, so it is possible that longer-term treatment could have had some benefit.

Conclusion

Forrester and Towell (2015) identified that stress can be the biggest cause of FIC due to the trigger effect on the body (Buffington et al, 1997), alterations in the urothelium (Buffington, 2011) and behavioural changes which affect toileting habits. Causes of stress can be traced to the cat's environment. Evidence for the treatment of FIC with medication or environmental modification is not strong, however it shows that long-term use of amitriptyline, use of pheromones and environmental modification can help reduce stress and thus reoccurrences of FIC. Veterinary nurses can be more in-volved in the ongoing treatment for these cases, with the setup of behaviour clinics, environmental assessments, and branching out to home visits and district veterinary nursing (Figure 4). This could also help with improving the general care and husbandry of cats across the UK.

Figure 4. Environmental assessments can be made by the veterinary nurse.

KEY POINTS

  • Feline idiopathic cystitis (FIC) is seen across all breeds and age ranges, with 5–6-year olds being commonly affected.
  • Stress can be the biggest cause of FIC, stimulating changes in the urothelium and behavioural alterations, leading to a reduction in urination.
  • Introducing a wet food is the only treatment that is associated with a significant reduction in clinical signs of FIC.
  • Further research is required into the true cause of FIC to identify further treatment options.
  • Reduction of stress can be implemented by the owner through veterinary nursing consultations; including behaviour clinics and environmental assessment through home visits and the utilisation of district nursing.